BR9808821A - Composições de combinação de lyme e usos - Google Patents

Composições de combinação de lyme e usos

Info

Publication number
BR9808821A
BR9808821A BR9808821-1A BR9808821A BR9808821A BR 9808821 A BR9808821 A BR 9808821A BR 9808821 A BR9808821 A BR 9808821A BR 9808821 A BR9808821 A BR 9808821A
Authority
BR
Brazil
Prior art keywords
compositions
antigen
pathogen
borrelia burgdorferi
lyme
Prior art date
Application number
BR9808821-1A
Other languages
English (en)
Inventor
Judy Jarecki-Black
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of BR9808821A publication Critical patent/BR9808821A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES COMBINADAS DE LYME E USOS"<D>. São descritas e reivindicadas composições contendo um antígeno de Borrelia burgdorferi, e métodos e uso das mesmas. O antígeno pode ser OspA. As composições podem conter pelo menos um antígeno adicional de um patógeno diferente do Borrelia burgdorferi. As composições são úteis para provocar uma resposta imunológica em um mamífero hospedeiro suscetível à doença de Lyme e ao patógeno mamífero diferente de Borrelia burgdorferi. Mamíferos hospedeiros adequados incluem cães, filhotes, cavalos e o antígeno adicional pode ser de um patógeno canino, eq³ino ou felino, tal como raiva, indisposição canina, adenovírus, coronavírus, parainfluenza e parvovírus. Não é observada nenhuma interferência significativa na eficácia.
BR9808821-1A 1997-03-05 1998-03-04 Composições de combinação de lyme e usos BR9808821A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/812,348 US6368603B1 (en) 1997-03-05 1997-03-05 Lyme combination compositions and uses
PCT/US1998/004135 WO1998039028A1 (en) 1997-03-05 1998-03-04 Lyme combination compositions and uses

Publications (1)

Publication Number Publication Date
BR9808821A true BR9808821A (pt) 2000-10-24

Family

ID=25209312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808821-1A BR9808821A (pt) 1997-03-05 1998-03-04 Composições de combinação de lyme e usos

Country Status (16)

Country Link
US (1) US6368603B1 (pt)
EP (1) EP0988051B1 (pt)
JP (1) JP4301415B2 (pt)
CN (1) CN1252730A (pt)
AT (1) ATE399021T1 (pt)
AU (1) AU746185B2 (pt)
BR (1) BR9808821A (pt)
CA (1) CA2283420C (pt)
DE (1) DE69839640D1 (pt)
DK (1) DK0988051T3 (pt)
ES (1) ES2310004T3 (pt)
HU (1) HU228709B1 (pt)
IL (2) IL131678A0 (pt)
PL (1) PL190989B1 (pt)
PT (1) PT988051E (pt)
WO (1) WO1998039028A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU758764B2 (en) * 1998-03-02 2003-03-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Epitope peptides immunogenic against (streptococcus pneumoniae)
AU5622800A (en) * 1999-06-18 2001-01-09 Med Immune, Inc. Combined decorin binding protein and outer surface protein compositions and methods of use
DE10162434A1 (de) * 2001-12-18 2003-09-25 November Ag Molekulare Medizin Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US20040197339A1 (en) * 2003-01-29 2004-10-07 Brown Paul R. Vaccine for Lyme disease
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
EP1718770B1 (en) 2004-02-19 2011-05-25 The Governors of the University of Alberta Leptin promoter polymorphisms and uses thereof
ES2343270T3 (es) 2005-04-25 2010-07-27 Merial Ltd. Vacunas contra el virus nipah.
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
EP3536704B1 (en) 2005-11-14 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
JP5177824B2 (ja) 2006-11-03 2013-04-10 シェーリング−プラウ・リミテッド イヌのライム病のワクチン
KR101445903B1 (ko) 2007-05-02 2014-09-29 메리얼 리미티드 향상된 발현 및 안정성을 갖는 ｄｎａ 플라스미드
US8871220B2 (en) 2009-04-03 2014-10-28 Merial Limited Newcastle disease virus vectored avian vaccines
US8623375B2 (en) * 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
CN103269714B (zh) 2010-08-31 2016-06-29 梅里亚有限公司 以新城疫病毒为载体的疱疹病毒疫苗
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
AU2012240246A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CN103945864A (zh) 2011-04-25 2014-07-23 先进生物学实验室股份有限公司 截短的hiv包膜蛋白(env)、其相关方法和组合物
US9669085B2 (en) 2011-06-01 2017-06-06 Merial Inc. Needle-free administration of PRRSV vaccines
WO2013025274A1 (en) 2011-08-12 2013-02-21 Merial Limited Vacuum -assisted preservation of biological products, in particular of vaccines
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
NZ731659A (en) 2014-11-03 2018-10-26 Merial Inc Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CN107922462B (zh) 2015-06-23 2022-03-18 勃林格殷格翰动物保健美国公司 含prrsv次要蛋白的重组病毒载体及其制造方法与用途
KR20180129949A (ko) 2016-04-14 2018-12-05 메리얼 인코포레이티드 항균성 폴리아미드 또는 옥테니딘 보존제를 함유하는 다중-투약량 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5266313A (en) 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
AU2917892A (en) 1991-11-12 1993-06-15 Regents Of The University Of Minnesota Recombinant vaccine against lyme disease
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US5728385A (en) * 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives

Also Published As

Publication number Publication date
ATE399021T1 (de) 2008-07-15
US6368603B1 (en) 2002-04-09
JP2001513112A (ja) 2001-08-28
EP0988051B1 (en) 2008-06-25
AU746185B2 (en) 2002-04-18
CA2283420C (en) 2008-07-22
HUP0001401A3 (en) 2005-10-28
HUP0001401A2 (en) 2000-07-28
PL190989B1 (pl) 2006-02-28
CN1252730A (zh) 2000-05-10
DK0988051T3 (da) 2008-10-13
JP4301415B2 (ja) 2009-07-22
DE69839640D1 (de) 2008-08-07
PL335731A1 (en) 2000-05-08
CA2283420A1 (en) 1998-09-11
EP0988051A4 (en) 2004-11-17
IL131678A0 (en) 2001-03-19
HU228709B1 (en) 2013-05-28
IL131678A (en) 2006-12-31
EP0988051A1 (en) 2000-03-29
WO1998039028A1 (en) 1998-09-11
PT988051E (pt) 2008-08-13
AU6680798A (en) 1998-09-22
ES2310004T3 (es) 2008-12-16

Similar Documents

Publication Publication Date Title
BR9808821A (pt) Composições de combinação de lyme e usos
AR046933A1 (es) Eficacia de humectacion mejorada mediante el uso de hidroxialquilurea
BRPI0410884A (pt) composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação
BR9809791A (pt) Compostos de fosfato de aminoalquil glucosamina e seu uso como auxiliares e imuno efetores
BRPI0013391B8 (pt) uso de polipeptídeos bcma na preparação de uma composição farmacêutica para tratar uma doença autoimune ou um distúrbio linfoproliferativo de célula b
CL2012001063A1 (es) Anticuerpo humano que se une a interleuquina 18 humana (il-18h), metodo de preparacion, acidos nucleicos que lo dosifican, composicion que los contiene, uso en la preparacion de un medicamento para tratar patologias mediadas por il-18h. (divisional sol. 316-01).
BR9610875A (pt) Modulares rxr seletivos - dimeros e processos para seu uso
BRPI0104743A8 (pt) composição para a tintura de oxidação das fibras queratínicas que compreende um polímero anfífilo catiônico, um álcool graxo oxialquilenado ou glicerolado e um solvente hidroxilado, composição pronta para o uso para a tintura de oxidação das fibras queratínicas, processo de tintura das fibras queratínicas e dispositivo com vários compartimentos ou kit para a tintura de oxidação das fibras queratínicas
BR9910083A (pt) Unidade de entrada, método para utilizar a mesma e sistema de entrada
ES2181234T3 (es) Producto de combinacion que asocia un acido nucleico a una sustancia que desorganiza la matriz extracelular para la terapia genica.
ES2165838T3 (es) Mejoras en o relativas a compuestos organicos.
BR0008011A (pt) Agente embranquecedor fluorescente, suapreparação e uso
BR9912539A (pt) Sistema equino para inseminação artificial não-cirúrgica
BR0312814A (pt) Levamisol / avermectinas ou similares em solvente de pirrolidona
CO5210920A1 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos
PT897667E (pt) Composicao para melhorar o pao
BRPI9914571B1 (pt) composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.
BR9816029A (pt) Composições detergente
BR0016419A (pt) Método para o aumento das respostas de imunização com relação a vacina do vìrus do herpes simplex
ES2023438B3 (es) Composiciones de goma de mascar que tienen liberacion acida secuencial.
MX9300306A (es) Bencimidazoles medicamentos que contienen estos compuestos y procedimiento para su preparacion.
BR0214126A (pt) Composiçáo farmacêutica para interferir na transmissão neuronal, preparação para o rejuvenescimento facial, e, métodos para interferir na transmissão neuronal, e na contração muscular
BR0010512A (pt) Uso de materiais mesoporosos tipo mcm-41 como catalisadores na oxidação de &#34;alfa&#34;-pineno e processo para a oxidação de &#34;alfa&#34;-pineno
CU23077A1 (es) Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
FR2712459B1 (fr) Litière biodégradable pour animaux, contenant des anas de lin ou de chanvre ou leurs mélanges imprégnés par une composition huileuse d&#39;hygiène et fixatrice.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]